RNA — Atrium Therapeutics Inc
In 2026 Q2, 3 of the 140 tracked hedge funds reported a position in Atrium Therapeutics Inc (RNA), worth $9.43M combined. Over the quarter 2 opened or added, 2 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| CRCM | $8.63M | 5.70% | NEW |
| Caxton Associates | $594.89K | 0.01% | NO CHANGE |
| Renaissance | $201.36K | 0.00% | NEW |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.